Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
70 studies found for:    apatinib
Show Display Options
Rank Status Study
1 Recruiting Effect of Rifampicin on the Pharmacokinetics of Apatinib
Condition: Neoplasms
Interventions: Drug: Apatinib Mesylate Tablets;   Drug: Rifampicin Capsules
2 Not yet recruiting Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)
Condition: Small Cell Lung Cancer
Intervention: Drug: Apatinib Mesylate tablet
3 Recruiting Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients
Condition: Colorectal Neoplasms
Intervention: Drug: Apatinib and XELOX combined treatment group
4 Recruiting Apatinib for Metastatic Esophageal Cancer.
Conditions: Esophageal Cancer;   Metastatic Esophageal Cancer;   Apatinib
Intervention: Drug: Apatinib
5 Not yet recruiting A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure
Condition: Hepatocellular Carcinoma
Intervention: Drug: Apatinib Mesylate Tablets
6 Recruiting The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: apatinib single agent
7 Recruiting Apatinib as Second-line Treatment of Advanced Pancreatic Cancer
Condition: Pancreatic Neoplasms
Intervention: Drug: Apatinib
8 Recruiting Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Apatinib single agent arm
9 Recruiting Effect of Itraconazole on the Pharmacokinetics of Apatinib
Condition: Neoplasms
Interventions: Drug: Apatinib Mesylate Tablets;   Drug: Itraconazole Capsules
10 Recruiting Apatinib for Advanced Non-squamous Head and Neck Cancer
Condition: Head and Neck Neoplasms
Intervention: Drug: Apatinib
11 Active, not recruiting The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
Condition: Stomach Neoplasms
Interventions: Biological: Cytokine-Induced Killer Cells;   Drug: Apatinib
12 Active, not recruiting The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
Condition: Adenocarcinoma of Lung
Interventions: Biological: Cytokine-Induced Killer Cells;   Drug: Apatinib
13 Completed A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: Apatinib
14 Active, not recruiting Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Apatinib
15 Recruiting The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: Apatinib;   Drug: Oxaliplatin;   Drug: S-1
16 Recruiting Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
Conditions: Osteosarcoma;   Metastasis
Intervention: Drug: apatinib
17 Recruiting Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer
Condition: Gastric Cancer
Intervention: Drug: apatinib
18 Not yet recruiting A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.
Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Apatinib
19 Recruiting Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma
Condition: Esophageal Squamous Cell Carcinoma
Interventions: Drug: Apatinib;   Drug: Irinotecan
20 Recruiting A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
Condition: Hepatocellular Carcinoma
Intervention: Drug: Apatinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.